Corcept Therapeutics files Rule 144 to sell 40,000 shares

Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc..

Rhea-AI Filing Summary

Corcept Therapeutics reported a proposed sale of 40,000 shares of Common Stock under Rule 144 via broker Stifel Nicolaus & Company Inc.. The filing also records a prior sale of 26,198 shares on 03/25/2026 for $1,311,825.

Key Figures

Proposed shares to be sold: 40,000 shares Aggregate amount shown nearby: $1,860,800.00 Shares sold in past 3 months: 26,198 shares +2 more

5 metrics

Proposed shares to be sold 40,000 shares Rule 144 proposed sale listed on the filing

Aggregate amount shown nearby $1,860,800.00 Numeric value appearing on the broker/security line in the excerpt

Shares sold in past 3 months 26,198 shares Sale dated 03/25/2026 listed under "Securities Sold During The Past 3 Months"

Proceeds from prior sale $1,311,825.00 Proceeds shown for the 03/25/2026 sale of 26,198 shares

Broker listed Stifel Nicolaus & Company Inc. Broker handling the proposed sale as shown on the filing

Key Terms

Rule 144, Stock Option Exercise, Securities Sold During The Past 3 Months

3 terms

Rule 144 regulatory

"proposed sale of 40,000 shares under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"07/06/2022 | Stock Option Exercise | Corcept Therapeutics Inc."

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Securities Sold During The Past 3 Months financial

"Common | 03/25/2026 | 26198 | 1311825.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who filed the Form 144 for Corcept Therapeutics (CORT)?

The Form 144 lists Joseph K. Belanoff as the reporting person. The filing names Stifel Nicolaus & Company Inc. as the broker handling the proposed sale of shares under Rule 144.

How many Corcept Therapeutics (CORT) shares are proposed for sale under this Form 144?

The filing specifies a proposed sale of 40,000 shares of Common Stock. The broker line in the notice identifies the trade routing and exchange as NASDAQ in the provided excerpt.

Does the Form 144 show any recent sales by the same holder for CORT?

Yes. The filing records a prior sale of 26,198 shares on 03/25/2026 with proceeds shown as $1,311,825. That sale is listed under "Securities Sold During The Past 3 Months."

What trade method or reason is listed for the securities in the Form 144?

The excerpt includes the phrase "Stock Option Exercise" dated 07/06/2022 and lists Cash as the method. The present Form 144, however, reports the proposed resale quantities and broker routing.

Which broker and exchange are named in the Corcept (CORT) Form 144?

The filing names Stifel Nicolaus & Company Inc. with an address in St. Louis and indicates NASDAQ as the exchange. Broker details appear on the broker/"Securities To Be Sold" line of the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 12:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001286199
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INC
SEC File Number	000-50679
Address of Issuer	101 REDWOOD SHORES PARKWAY REDWOOD CITY CALIFORNIA 94065
Phone	650.688.8803
Name of Person for Whose Account the Securities are To Be Sold	BELANOFF JOSEPH K
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N Broadway St. Louis MO 63102	40000	1860800.00	107360000	05/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/06/2022	Stock Option Exercise	Corcept Therapeutics Inc.			40000	07/06/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph K. Belanoff 101 Redwood Shores Parkway Redwood City CA 94065	Common	03/25/2026	26198	1311825.00

144: Remarks and Signature

Remarks
Date of Notice	05/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Toni Dobel, as a duly authorized representative of STIFEL, as attorney-in-fact for Joseph K. Belanoff
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)